Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10878073 | 0.81 | TDP1 (0.48) | TDP1MMP1MMP2MMP3MMP9 | |
| Isocitric Acid SCHEMBL29645996 | 0.80 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6TSHR | |
| Isocitric Acid SCHEMBL27894954 | 0.80 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6TSHR | |
| Isocitric Acid SCHEMBL2794437 | 0.80 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6TSHR | |
| Isocitrate SCHEMBL8373 | 0.80 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6TSHR | |
| Isocitric Acid SCHEMBL30700829 | 0.80 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6TSHR | |
| Isocitrate SCHEMBL1289944 | 0.80 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6TSHR | |
| Isocitric Acid SCHEMBL12927570 | 0.80 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6TSHR | |
| Isocitric Acid SCHEMBL6249818 | 0.80 | TDP1 (0.68) | TDP1SMN1; SMN2SLC22A6TSHR | |
| SCHEMBL1707888 | 0.80 | TDP1 (0.46) | TDP1MMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012046062-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | SHIRE, LLC (US) | 2012-04-12 | — | — | WO | disclosed |